Report for: Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Title	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
Published in	Molecular Cancer, July 2010
DOI	10.1186/1476-4598-9-196
Pubmed ID	20649976
Authors	María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, Gema Moreno-Bueno, Juana M Flores, Isabel García-Real, José Palacios, Santos Mañes, Manuel Guzmán, Cristina Sánchez

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 192 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
United States	52	27%
Indonesia	12	6%
United Kingdom	10	5%
Spain	9	5%
Canada	8	4%
Colombia	3	2%
Australia	3	2%
Georgia	2	1%
Mexico	2	1%
Other	10	5%
Unknown	81	42%

Demographic breakdown

Type	Count	As %
Members of the public	170	89%
Practitioners (doctors, other healthcare professionals)	16	8%
Scientists	3	2%
Science communicators (journalists, bloggers, editors)	2	1%
Unknown	1	<1%

Mendeley readers

The data shown below were compiled from readership statistics for 210 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
United States	3	1%
United Kingdom	2	<1%
South Africa	1	<1%
Brazil	1	<1%
Unknown	203	97%

Demographic breakdown

Readers by professional status	Count	As %
Student > Bachelor	41	20%
Researcher	33	16%
Student > Ph. D. Student	29	14%
Student > Master	24	11%
Other	18	9%
Other	33	16%
Unknown	32	15%

Readers by discipline	Count	As %
Agricultural and Biological Sciences	43	20%
Biochemistry, Genetics and Molecular Biology	38	18%
Medicine and Dentistry	29	14%
Pharmacology, Toxicology and Pharmaceutical Science	12	6%
Psychology	8	4%
Other	37	18%
Unknown	43	20%

Attention Score in Context

This research output has an Altmetric Attention Score of 422. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2022.

All research outputs

#58,215

of 23,308,124 outputs

Outputs from Molecular Cancer

of 1,757 outputs

Outputs of similar age

#102

of 95,848 outputs

Outputs of similar age from Molecular Cancer

of 24 outputs

Altmetric has tracked 23,308,124 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 1,757 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done particularly well, scoring higher than 99% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,848 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.

We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context